The co-founder and CEO of Known Medicine dissects the art and science of how profiling biomarkers, epigenetics and the microenvironment may provide the synergy needed to revolutionize the oncologic landscape.
0:17 Avicenna’s impact on precision medicine
3:56 The state of lung cancer precision medicine
5:13 What does precision medicine mean?
6:55 Differing biomarkers
11:47 Biomarkers as screening tools
13:50 Targeting lung cancer mutations
17:33 Combining generations of agents
22:50 The cancer microbiome
24:36 Hurdles to precision medicine access
28:01 The burden of delayed diagnosis
32:30 New technologies
36:04 Closing thoughts
37:01 Outro
Lung cancer treatment is on the precipice of unheralded advancement in its field. The intersection of advanced diagnostics, targeted immunotherapy, and implementation of artificial intelligence-borne pathology has created a possibility of concise, individualized care.
Or, as many refer to it, precision medicine.
In this newest episode of Lungcast, American Lung Association (ALA) chief medical officer Al Rizzo, MD, sits down with Andrea Mazzocchi, PhD, co-founder and chief executive officer of Known Medicine, and adjunct professor at Wake Forest University.
After reviewing the ever-long beneficial teachings of Persian scientist Avicenna and his influence on modern precision medicine, Rizzo and Mazzocchi discuss the ins and outs of emerging lung cancer tools and capabilities.
Lungcast is a monthly respiratory health podcast series from the ALA, produced by HCPLive.
Subscribe or listen to Lungcast on your favorite platforms:
